Among the b-lactamase enzymes producing resistance to b-lactam agents, the genetically mobile metallo-blactamases are among the most feared because of their ability to hydrolyze virtually all drugs in that class, including the carbapenems [1] . The latter group has been generally reserved for use in treating severe infections or those cases caused by organisms known to be resistant to the most advanced penicillins or cephalosporins. Because of these organisms' ability to inactivate so many agents, any increase in their prevalence would drastically compromise the ability to effectively treat hospital-or community-acquired infections caused predominantly by gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter species, and Serratia marcescens, among others. As a result of their geographic spread, these enzymes, as a mechanism of resistance, are among the greatest concerns to the medical community [2, 3] .
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As part of a structured objective designed to determine the prevalence and emerging risks of metallo-blactamases, the SENTRY Antimicrobial Surveillance
Program routinely screens gram-negative bacilli with elevated carbapenem and ceftazidime MICs for the presence of metallo-enzymes [4] [5] [6] [7] . Starting in late 2001, isolates from sentinel hospitals worldwide were phenotypically characterized, susceptibility tested, and ribotyped [8] . The genetic basis for resistance was confirmed or determined by amplification and sequencing of the variable region of class 1 or 3 integrons and by cloning of novel resistance determinants [9, 10] .
Over the past 3 years, the SENTRY Program has documented a worldwide increase in the rates of occurrence and number of types of metallo-b-lactamases (table 1) , a development that is of concern [4, 11, 12] . The increase in resistance to carbapenems by any mechanism has been observed in the Asian-Pacific, European, and Latin American geographic areas. The rate of resistance to carbapenems among participating centers in Japan increased from 19.3% in 1998 to 38% in 2002, whereas 44.8% of Brazilian P. aeruginosa isolates were found to be imipenem-resistant [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The proportion of carbapenem resistance attributable to metallo-b-lactamases increased significantly as well; the presence of metallo-b-lactamases accounted for resistance in 43.9% of Brazilian and 39.1% of Italian imipenem-resistant P. aeruginosa samples [23] . These percentages represent a dramatic escalation in the fraction of resistance caused by these enzymes. The first metallo b-lactamase (VIM-7) in the United States (found in Texas) was also reported by SENTRY Program investigators in 2004 [9] . Metallo-b-lactamase-producing isolates have also been identified in Argentina, Greece, France, Poland, and Germany [4, 24] . An increase in the diversity of metallo-b-lactamases has also been observed. The emergence of several novel enzymes within the 2 established enzyme types (VIM and IMP) were discovered; IMP-2 and IMP-11 were detected in Japanese P. aeruginosa and S. marcescens isolates, respectively, and IMP-13 was noted in Italian P. aeruginosa strains [20, 25, 26] . This study also characterized 2 additional, previously undescribed metallo-b-lactamase types, GIM-1 and SPM-1, the latter of which was identified in a Brazilian P. aeruginosa pediatric urine isolate [10, 11] .
The rapid dissemination of metallo-b-lactamases at several sites worldwide has clearly occurred. Epidemiological characterization of Italian isolates revealed the extent of inter-and intrahospital dissemination of metallo-b-lactamase-producing strains, whereas the rapid dissemination of SPM-1-producing P. aeruginosa in and between hospitals was tracked in Brazil, where this enzyme predominates [4, 15, 23] .
An increase in both the extent and diversity of metallo-blactamases severely limits treatment options on at least 3 continents (Asia, Europe, and South America), resulting in use of combinations of antimicrobial agents, in an attempt to achieve synergy between drugs that are otherwise ineffective. Alternatively, older, more-toxic drugs, such as polymyxin B and colistin, are being used. Because of the prevalence of coresistances, metallo-b-lactamase-producing isolates are often resistant to all other treatment options, signaling the need for the development of new, potent therapeutic agents with novel modes of action. Unfortunately, there are few new candidate drugs in development that target gram-negative pathogens, largely as a result of disinterest by large pharmaceutical companies that foresee substantial developmental outlays and limited future profits in the antimicrobial market [1] [2] [3] [4] .
To address the impending crisis, an interim strategy involving improved infection control, expanded public health infrastructure, promotion of prescription discipline, comprehensive resistance surveillance programs (such as the SENTRY Program), and incentives for development of antimicrobials must be implemented globally. Government, industry, and academia must work together to avoid the catastrophic situation in which no life-saving antimicrobial therapeutic options are available.
